-
FDA moving to 'risk-based' inspections even as valsartan scare adds new wrinkle to oversight
fiercepharma
January 31, 2019
FDA inspections of generic drug plants are on the rise and should continue to increase through 2019, Commissioner Scott Gottlieb said this week in a series of tweets.
-
Prinston Issues Recall of Irbesartan, Irbesartan HCTZ Tablets
americanpharmaceuticalreview
January 23, 2019
Prinston Pharmaceutical has initiated a voluntary recall of one lot of Irbesartan and seven lots of Irbesartan HCTZ Tablets to the consumer level due to the detection of trace amount of an unexpected impurity found in ....
-
Torrent Pharmaceuticals Issues Recall of Losartan Potassium Tablets
americanpharmaceuticalreview
December 24, 2018
orrent Pharmaceuticals is voluntarily recalling two lots of Losartan potassium tablets, USP to the consumer level due to the detection of trace amounts of.....
-
Chinese API Market Growing Strongly, CPhI China Assisting Enterprises with the Transformation, Innovation, and Comprehensive Upgrading
en-cphi.cn
December 17, 2018
The main business income of API manufacturing in China has reached RMB 499.1 billion, growing by 14.68% year on year; and the export of APIs has reached USD 29.1 billion, growing by 13.7% year on year.
-
Chinese drugmaker pours $145M into plant with plan to produce innovative biologics
fiercepharma
December 06, 2018
A Chinese maker of heparin, APIs and some finished drugs is launching the second phase of its manufacturing plant, investing nearly $150 million as it moves into producing innovative biologic drugs for the Chinese market.
-
Teva Announces Recall
americanpharmaceuticalreview
November 29, 2018
Teva Pharmaceuticals has initiated a voluntary recall in the United States, to the patient level, of all lots of Amlodipine / Valsartan combination tablets and Amlodipine / Valsartan.....
-
Cambrex to Acquire Halo Pharma, Adding Drug Development and Finished Dosage Capabilities to Global API Manufacturing Network
pharmafocusasia
November 28, 2018
Cambrex Corporation, a leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), today announced......
-
Cambrex Buys Avista for $252M
contractpharma
November 27, 2018
Cambrex?has entered into a definitive agreement to acquire?Avista Pharma Solutions?for roughly $252 million. Avista is a portfolio company of Ampersand Capital Partners.
-
ASIT Biotech Adds GMP Manufacturing Unit
contractpharma
November 27, 2018
ASIT biotech?has installed and qualified a clean room with the equipment to produce, in compliance with GMP requirements, the API for the Phase I/II studies in house dust mite and peanut allergies treatment. ?
-
Acquisition boosts Cambrex's early-stage development capabilities
cphi-online
November 27, 2018
Avista is a portfolio company of Ampersand Capital Partners, a leading healthcare-focused private equity firm. With this acquisition, Cambrex will enter the large and growing market
ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
Pharma Sources Insight July 2025
